In the current work, we aimed at testing whether KLK6, KLK8 and KLK10 levels in CSF are able to differentiate between AD patients with positive AD biomarkers and NC, and whether KLKs are associated with the established AD biomarkers. This evidence concerns the gene KLK6 and Alzheimer disease.